FAQ on Lantern Pharma's Phase 2 HARMONIC Trial Completion in Japan

What is the Phase 2 HARMONIC trial about?

The Phase 2 HARMONIC trial evaluates LP-300 in combination with carboplatin and pemetrexed for never-smoker non-small cell lung cancer (NSCLC) patients who have progressed after tyrosine kinase inhibitors.

Why is the completion of targeted enrollment in Japan significant?

Completing enrollment ahead of schedule in Japan validates Lantern Pharma’s international expansion strategy into regions with a higher prevalence of never-smoker NSCLC, such as Japan and Taiwan.

How many patients are enrolled in the global trial?

The global trial aims to enroll approximately 90 patients, with 10 already enrolled across five sites in Japan, including the National Cancer Center Japan.

What does early U.S. data show about LP-300?

Early U.S. data indicates an 86% clinical benefit rate, including a durable complete response lasting nearly two years.

Who is leading Lantern Pharma?

Panna Sharma is the CEO of Lantern Pharma, overseeing the company’s AI-driven development of targeted cancer therapies.

What is Lantern Pharma’s proprietary platform?

Lantern Pharma utilizes its proprietary RADR® platform, an AI and machine learning system with over 100 billion oncology-focused data points, to accelerate oncology drug discovery and development.

Where can I find more information about Lantern Pharma?

More information about Lantern Pharma (NASDAQ: LTRN) is available in the company’s newsroom at https://ibn.fm/LTRN.

What is the potential market impact of Lantern Pharma’s pipeline?

Lantern Pharma’s AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD, offering life-changing therapies to hundreds of thousands of cancer patients worldwide.